PURPOSE: Women with a BRCA1 or BRCA2 mutation are at high risk for breast cancer and must make important decisions about breast cancer prevention and screening. In the current study, we report a multisite, randomized, controlled trial evaluating the effectiveness of a decision aid for breast cancer prevention in women with a BRCA mutation with no previous diagnosis of cancer. METHODS: Within 1 month of receiving a positive BRCA result, women were randomized to receive either usual care (control group) or decision aid (intervention group). Participants were followed at 3, 6, and 12 months; were asked about preventive measures; and completed standardized questionnaires assessing decision making and psychosocial functioning. RESULTS: One hundred fifty women were randomized. Mean cancer-related distress scores were significantly lower in the intervention group compared with the control group at 6 months (P = 0.01) and at 12 months postrandomization (P = 0.05). Decisional conflict scores declined over time for both groups and at no time were there statistical differences between the two groups. CONCLUSION: The decision aid for breast cancer prevention in women with a BRCA1 or BRCA2 mutation is effective in significantly decreasing cancer-related distress within the year following receipt of positive genetic test results.Genet Med 19 3, 330-336.
PURPOSE: Women with a BRCA1 or BRCA2 mutation are at high risk for breast cancer and must make important decisions about breast cancer prevention and screening. In the current study, we report a multisite, randomized, controlled trial evaluating the effectiveness of a decision aid for breast cancer prevention in women with a BRCA mutation with no previous diagnosis of cancer. METHODS: Within 1 month of receiving a positive BRCA result, women were randomized to receive either usual care (control group) or decision aid (intervention group). Participants were followed at 3, 6, and 12 months; were asked about preventive measures; and completed standardized questionnaires assessing decision making and psychosocial functioning. RESULTS: One hundred fifty women were randomized. Mean cancer-related distress scores were significantly lower in the intervention group compared with the control group at 6 months (P = 0.01) and at 12 months postrandomization (P = 0.05). Decisional conflict scores declined over time for both groups and at no time were there statistical differences between the two groups. CONCLUSION: The decision aid for breast cancer prevention in women with a BRCA1 or BRCA2 mutation is effective in significantly decreasing cancer-related distress within the year following receipt of positive genetic test results.Genet Med 19 3, 330-336.
Authors: Sahar J Alothman; Weisheng Wang; David S Goerlitz; Md Islam; Xiaogang Zhong; Archana Kishore; Redha I Azhar; Bhaskar V Kallakury; Priscilla A Furth Journal: Cancer Prev Res (Phila) Date: 2017-03-10
Authors: Salma Shickh; Marc Clausen; Chloe Mighton; Selina Casalino; Esha Joshi; Emily Glogowski; Kasmintan A Schrader; Adena Scheer; Christine Elser; Seema Panchal; Andrea Eisen; Tracy Graham; Melyssa Aronson; Kara M Semotiuk; Laura Winter-Paquette; Michael Evans; Jordan Lerner-Ellis; June C Carroll; Jada G Hamilton; Kenneth Offit; Mark Robson; Kevin E Thorpe; Andreas Laupacis; Yvonne Bombard Journal: BMJ Open Date: 2018-04-26 Impact factor: 2.692
Authors: Marline G Harmsen; Miranda P Steenbeek; Nicoline Hoogerbrugge; Helena C van Doorn; Katja N Gaarenstroom; M Caroline Vos; Leon F A G Massuger; Joanne A de Hullu; Rosella P M G Hermens Journal: Health Expect Date: 2017-12-27 Impact factor: 3.377
Authors: A Isselhard; M Töpper; B Berger-Höger; A Steckelberg; H Fischer; F Vitinius; K Beifus; J Köberlein-Neu; R Wiedemann; K Rhiem; R Schmutzler; S Stock Journal: Trials Date: 2020-06-08 Impact factor: 2.279
Authors: David Chelmow; Mark D Pearlman; Amy Young; Laura Bozzuto; Sandra Dayaratna; Myrlene Jeudy; Mallory E Kremer; Dana Marie Scott; Julia Sage O'Hara Journal: Obstet Gynecol Date: 2020-06 Impact factor: 7.623